DUPIXENT 300 MG / 2 ML
DUPILUMAB : 300 MG / 2 ML · DIN 02510049 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is DUPIXENT?
DUPIXENT 300 MG / 2 ML contains DUPILUMAB : 300 MG / 2 ML. It is listed in the Health Canada Drug Product Database under DIN 02510049, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 27-May-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DUPIXENT used for?
DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma. DUPIXENT is indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. DUPIXENT is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery. DUPIXENT is indicated for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). DUPIXENT is indicated for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT is indicated for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who remain symptomatic despite H1 antihistamine treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02510049 |
|---|---|
| Brand name | DUPIXENT |
| Generic / active ingredient | DUPILUMAB : 300 MG / 2 ML |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 300 MG / 2 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | D11AH05 DUPILUMAB |
| AHFS class | 84:06.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-May-2021 |
| Original market date | 2021-05-27 00:00:00 |
How is it stored and handled?
null
How is it supplied?
DUPIXENT is available in packs containing 1 or 2 pre-filled syringes with needle shield or pre-filled pens.
What can be used instead?
Other Canadian products sharing ATC code D11AH05 DUPILUMAB. 4 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DUPIXENT | 200 MG / 1.14 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02492504 |
| DUPIXENT | 200 MG / 1.14 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02524252 |
| DUPIXENT | 300 MG / 2 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02470365 |
| DUPIXENT | 100 MG / 0.67 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED PRE MARKET | DIN 02526190 |
Who else supplies DUPILUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DUPILUMAB appears in 86 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.